<DOC>
	<DOCNO>NCT00036179</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy FK463 treatment patient confirm candidemia invasive candidiasis .</brief_summary>
	<brief_title>Study FK463 Treatment Candidemia Invasive Candidiasis</brief_title>
	<detailed_description>This open-label , non-comparative study intravenous FK463 . Enrollment include least 100 patient evaluable efficacy .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<criteria>Inclusion Criteria Has Candidemia invasive candidiasis document typical clinical sign symptom confirm fungal culture histologic confirmation Exclusion Criteria Has abnormal liver test parameter , e.g. , AST ALT &gt; 10 time upper limit normal Has life expectancy judge less 5 day De novo patient receive systemic antifungal agent treatment episode candidemia invasive candidiasis 48 hour prior first dose FK463 ; efficacy failure patient receive = &lt; 5 day prior systemic antifungal therapy treatment episode candidemia invasive candidiasis Require treatment topical systemic antifungal agent condition candidemia invasive candidiasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Candidemia</keyword>
	<keyword>Anti-Fungal</keyword>
</DOC>